Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer.
Moiseyenko FV, Kuligina ES, Zhabina AS, Belukhin SA, Laidus TA, Martianov AS, Zagorodnev KA, Sokolova TN, Chuinyshena SA, Kholmatov MM, Artemieva EV, Stepanova EO, Shuginova TN, Volkov NM, Yanus GA, Imyanitov EN. Moiseyenko FV, et al. Among authors: kholmatov mm. Int J Clin Oncol. 2022 May;27(5):850-862. doi: 10.1007/s10147-022-02128-6. Epub 2022 Feb 16. Int J Clin Oncol. 2022. PMID: 35171360 Free PMC article.
Content of circulating tumor DNA depends on the tumor type and the dynamics of tumor size, but is not influenced significantly by physical exercise, time of the day or recent meal.
Kuligina ES, Meerovich R, Zagorodnev KA, Kholmatov MM, Sokolova TN, Laidus TA, Romanko AA, Martianov AS, Anisimova MO, Zaitseva OA, Yatsuk OS, Yanus GA, Imyanitov EN. Kuligina ES, et al. Among authors: kholmatov mm. Cancer Genet. 2021 Aug;256-257:165-178. doi: 10.1016/j.cancergen.2021.05.014. Epub 2021 May 28. Cancer Genet. 2021. PMID: 34186498
Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants.
Mitiushkina NV, Tiurin VI, Iyevleva AG, Kholmatov MM, Filippova EA, Moiseyenko FV, Levchenko NE, Sardaryan IS, Odintsova SV, Lozhkina AM, Volkov NM, Karaseva NA, Moiseyenko VM, Orlov SV, Imyanitov EN. Mitiushkina NV, et al. Among authors: kholmatov mm. Biochimie. 2018 Nov;154:19-24. doi: 10.1016/j.biochi.2018.07.018. Epub 2018 Jul 30. Biochimie. 2018. PMID: 30071258
Comparative analysis of expression of mutant and wild-type alleles is essential for reliable PCR-based detection of MET exon 14 skipping.
Mitiushkina NV, Kholmatov MM, Tiurin VI, Romanko AA, Yatsuk OS, Sokolova TN, Ivantsov AO, Kuligina ES, Stepanov IA, Belyaev AM, Togo AV, Imyanitov EN. Mitiushkina NV, et al. Among authors: kholmatov mm. Biochimie. 2019 Oct;165:267-274. doi: 10.1016/j.biochi.2019.08.014. Epub 2019 Aug 28. Biochimie. 2019. PMID: 31472177
Comprehensive evaluation of the test for 5'-/3'-end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer.
Mitiushkina NV, Romanko AA, Preobrazhenskaya EV, Tiurin VI, Ermachenkova TI, Martianov AS, Mulkidjan RS, Sokolova TN, Kholmatov MM, Bizin IV, Ivantsov AO, Yatsuk OS, Zaitseva OA, Iyevleva AG, Kuligina ES, Imyanitov EN. Mitiushkina NV, et al. Among authors: kholmatov mm. Cancer Med. 2022 Sep;11(17):3226-3237. doi: 10.1002/cam4.4686. Epub 2022 Mar 23. Cancer Med. 2022. PMID: 35322575 Free PMC article.